Extracellular vesicles and microRNAs in cancer progression

Advances in clinical chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Modern Emerging Biosensing Methodologies for the Early Diagnosis and Screening of Ovarian Cancer

Biosensors, Journal Year: 2025, Volume and Issue: 15(4), P. 203 - 203

Published: March 21, 2025

Ovarian cancer (OC) is one of the leading causes gynecological cancer-related death worldwide. Late diagnosis at advanced stages OC reason for a higher mortality rate. Earlier and proper treatment are important improving prognosis patients. Biosensors offer accurate, low-cost, rapid, user-friendly devices that can be employed detection OC-specific biomarkers in early stage. Therefore, it to consider potential biological fluids confirm prognosis. Out many biomarkers, most commonly tested clinically antigen 125 (CA-125). However, CA-125 considered poor biomarker diagnosis. Several biosensing methods were developed sensitive quantitative each biomarker. In abnormal expression patients, nucleic acids, enzymes, cells, exosomes used as target construction biosensors. This review focuses on development various using multiple methods. Here, we describe origin significance OC-associated working principle biosensors, classification biosensors based their recognition elements signal transducers. The modes sensitivity sensors discussed. Finally, challenges fabrication, obstacles clinical application, future prospects

Language: Английский

---

Advancing ovarian cancer management: Role of nucleic acid biomarkers and novel therapeutic approaches

Gene Reports, Journal Year: 2025, Volume and Issue: unknown, P. 102241 - 102241

Published: May 1, 2025

Language: Английский

---

Ovarian cancer and the heart: pathophysiology, chemotherapy-induced cardiotoxicity, and new therapeutic strategies

Journal of Ovarian Research, Journal Year: 2025, Volume and Issue: 18(1)

Published: April 5, 2025

Ovarian Cancer (OC) is recognized as the most lethal gynecologic malignancy, characterized by numerous genetic mutations that trigger uncontrolled cellular growth and replication. Emerging evidence suggests non-coding RNAs including miRNAs lncRNAs significantly influence OC through their multiple roles tumor initiation, progression, metastasis, immune evasion, chemoresistance, making them promising diagnostic markers therapeutic targets. The primary approach to treating typically involves cytoreductive surgery followed chemotherapy. However, chemotherapeutic agents, particularly anthracyclines such doxorubicin (DOX), are known for cardiotoxic effects, which can range from acute chronic, potentially leading heart failure death. To enhance overall treatment response minimize cardiotoxicity, alternative strategies have been explored. These include use of liposomal (DOXIL) a substitute DOX, various radiotherapies, immunotherapies, co-administration angiotensin-converting enzyme inhibitors and/or beta-blockers. Phosphodiesterase-5 (PDE5i) also demonstrated efficacy in reducing cardiotoxicity linked cancer treatments promoting apoptosis cells across types. Although there no current clinical trial directly examining impact PDE5i on OC, however emerging therapies Withaferin A, PARP inhibitors, nanoparticle combination therapy show promise. Additional research essential develop both effective against less harmful heart.

Language: Английский

---

Folate Receptor Alpha—A Secret Weapon in Ovarian Cancer Treatment?

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(22), P. 11927 - 11927

Published: Nov. 6, 2024

Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy worldwide. Due to its nonspecific symptoms and unreliable screening tools, EOC not diagnosed at an early stage in cases. Unfortunately, despite achieving initial remission after debulking surgery platinum-based chemotherapy, patients experience recurrence of disease. The limited therapy approaches have encouraged scientists search for new detection therapeutic strategies. In this review, we discuss role folate receptor alpha (FRα) development potential application as a biomarker molecular target designing treatment methods. We summarize mechanisms action various strategies based on FRα, including MABs (monoclonal antibodies), ADCs (antibody-drug conjugates), FDCs (folate-drug SMDCs (small molecule-drug vaccines, CAR-T (chimeric antigen T) cells, present significant clinical trials some FRα-based drugs. Furthermore, pros cons different FR-based therapies, highlighting mirvetuximab soravtansine (MIRV) currently promising EOC-targeting drug.

Language: Английский

---

Diagnostic Utility of Metalloproteinases from Collagenase Group (MMP-1, MMP-8 and MMP-13) in Biochemical Diagnosis of Ovarian Carcinoma

Cancers, Journal Year: 2024, Volume and Issue: 16(23), P. 3969 - 3969

Published: Nov. 26, 2024

Ovarian carcinoma (OC) has an unfavorable prognosis due to lack of screening and asymptomatic course. New diagnostic methods are being sought enable earlier diagnosis this condition. The purpose study was determine the utility collagenases (MMP-1, MMP-8 MMP-13) in OC compared HE4 CA125 ROMA.

Language: Английский

---